5MC Stock Overview
A biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Leap Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.60 |
52 Week High | US$4.22 |
52 Week Low | US$1.03 |
Beta | 0.42 |
11 Month Change | -23.81% |
3 Month Change | -33.88% |
1 Year Change | -38.13% |
33 Year Change | -88.46% |
5 Year Change | -89.60% |
Change since IPO | -97.58% |
Recent News & Updates
Recent updates
Shareholder Returns
5MC | DE Biotechs | DE Market | |
---|---|---|---|
7D | -6.4% | 4.4% | 0.9% |
1Y | -38.1% | -16.6% | 3.0% |
Return vs Industry: 5MC underperformed the German Biotechs industry which returned -14.3% over the past year.
Return vs Market: 5MC underperformed the German Market which returned 3.9% over the past year.
Price Volatility
5MC volatility | |
---|---|
5MC Average Weekly Movement | 11.8% |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5MC's share price has been volatile over the past 3 months.
Volatility Over Time: 5MC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 54 | Doug Onsi | www.leaptx.com |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd.
Leap Therapeutics, Inc. Fundamentals Summary
5MC fundamental statistics | |
---|---|
Market cap | €65.21m |
Earnings (TTM) | -€49.97m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs 5MC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5MC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$53.37m |
Earnings | -US$53.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.39 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 5MC perform over the long term?
See historical performance and comparison